MENU
Showcases Stock ranks Forex

Redhill Biophrma ADR (RDHL)
0.5299  0.018 (3.48%) 03-28 16:00
Open: 0.5 Pre. Close: 0.5121
High: 0.5498 Low: 0.5
Volume: 498,473 Market Cap: 10(M)
Stock Technical Analysis
Overall:     
Target: Six months: 0.67
One year: 0.76
Support: Support1: 0.45
Support2: 0.38
Resistance: Resistance1: 0.57
Resistance2: 0.65
Pivot: 0.52
Moving Averages: MA(5): 0.49
MA(20): 0.53
MA(100): 0.84
MA(250): 1.23
MACD: MACD(12,26): -0.03
Signal(12,26,9): -0.04
%K %D: %K(14,3): 49.54
%D(3): 29.29
RSI: RSI(14): 46.65
52-Week: High: 4.55
Low: 0.257
Change(%): -88.1
Average Vol(K): 3-Month: 1325
10-Days: 472
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.551 - 0.553 0.553 - 0.555
Low: 0.495 - 0.497 0.497 - 0.499
Close: 0.526 - 0.53 0.53 - 0.534
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

[ RDHL ] has closed below upper band by 38.6%. Bollinger Bands are 86.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Stock chart
Stock News
Thu, 28 Mar 2024
RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for ... - The Globe and Mail

Mon, 25 Mar 2024
RedHill Biopharma to Present at the BIO-Europe 2021 Conference - The Globe and Mail

Wed, 29 Nov 2023
RDHL Stock Quote Price and Forecast - CNN

Tue, 28 Nov 2023
Healthcare Stocks Making Moves Tuesday: RDHL, ICCM, GYRE, CDIO, AXLA, CABA, BDRX, SEEL - InvestorsObserver

Mon, 27 Nov 2023
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to ... - PR Newswire

Fri, 17 Mar 2023
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Drug Manufacturers - Specialty & Generic
Shares Out. (M) 29.70
Shares Float (M) 1200.00
% Held by Insiders
% Held by Institutions 6.70
Shares Short (K) 376
Shares Short Prior Month (K) 1110
Stock Financials
EPS -8.000
Book Value (p.s.) 1.090
Profit Margin 32.37
Operating Margin -245.43
Return on Assets (ttm) -17.2
Return on Equity (ttm)
Qtrly Rev. Growth -90.2
Gross Profit (p.s.)
Sales Per Share 1.203
EBITDA (p.s.) -0.810
Qtrly Earnings Growth
Operating Cash Flow (M) -26.22
Levered Free Cash Flow (M) -38.70
Stock Valuation
PE Ratio -0.07
PEG Ratio
Price to Book value 0.49
Price to Sales 0.44
Price to Cash Flow -0.60
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android